Trials / Completed
CompletedNCT05460325
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects With Hereditary Angioedema
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanadelumab | Lanadelumab subcutaneous injection |
Timeline
- Start date
- 2022-06-22
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
- First posted
- 2022-07-15
- Last updated
- 2024-12-13
- Results posted
- 2024-12-13
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05460325. Inclusion in this directory is not an endorsement.